Interpace Diagnostics Group (NASDAQ:IDXG) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
Insider & Institutional Ownership
9.7% of Sensus Healthcare shares are owned by institutional investors. 48.0% of Interpace Diagnostics Group shares are owned by insiders. Comparatively, 31.2% of Sensus Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Interpace Diagnostics Group has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, Sensus Healthcare has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500.
This table compares Interpace Diagnostics Group and Sensus Healthcare’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Interpace Diagnostics Group||-113.94%||-93.71%||-38.93%|
Earnings & Valuation
This table compares Interpace Diagnostics Group and Sensus Healthcare’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Interpace Diagnostics Group||$24.08 million||0.85||-$26.73 million||($5.58)||-0.91|
|Sensus Healthcare||$27.26 million||1.27||-$1.70 million||($0.10)||-21.00|
Sensus Healthcare has higher revenue and earnings than Interpace Diagnostics Group. Sensus Healthcare is trading at a lower price-to-earnings ratio than Interpace Diagnostics Group, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings and recommmendations for Interpace Diagnostics Group and Sensus Healthcare, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Interpace Diagnostics Group||0||0||5||0||3.00|
Interpace Diagnostics Group presently has a consensus target price of $9.06, suggesting a potential upside of 79.10%. Sensus Healthcare has a consensus target price of $4.10, suggesting a potential upside of 95.24%. Given Sensus Healthcare’s higher possible upside, analysts clearly believe Sensus Healthcare is more favorable than Interpace Diagnostics Group.
Sensus Healthcare beats Interpace Diagnostics Group on 9 of the 14 factors compared between the two stocks.
About Interpace Diagnostics Group
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
About Sensus Healthcare
Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary robotic intraoperative radiation therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.